- ►novonordisk.co.uk [PDF] T Heise, L Nosek, BB Rønn, L Endahl, L … - Diabetes, 2004 - Am Diabetes Assoc The aim of this randomized double-blind study was to compare the within-subject
variability of the glucose-lowering effect of a novel insulin analog, insulin
detemir, with that of insulin glargine and NPH insulin in people with type ... Cited by 293 - Related articles - BL Direct - All 13 versions
- ►viamedica.pl [PDF] - Free from Publisher P Vague, JL Selam, S Skeie, I De Leeuw, JWF … - Diabetes Care, 2003 - Am Diabetes Assoc 1 Hôpital de la Timone, Service Nutrition Endocrinologie et Maladies
Metabolique, Marseilles, France 2 Hotel Dieu, Service de Diabétologie, Paris,
France 3 Hjertelaget Research Foundation, Stavanger, Norway 4 Department of ... Cited by 232 - Related articles - BL Direct - All 8 versions
- ►pr-ide.be [PDF] K Hermansen, P Fontaine, KK Kukolja, V … - Diabetologia, 2004 - Springer Aims/hypothesis. The aim of the trial was to compare the efficacy and
tolerability of two types of basal-bolus therapy, using either the soluble
long-acting basal insu- lin analogue, insulin detemir, in combination with ... Cited by 231 - Related articles - BL Direct - All 10 versions
T Haak, A Tiengo, E Draeger, M Suntum, W … - Diabetes Obesity and Metabolism, 2005 - fe-inzichten.nl Aim: The aim of this study was to compare the efficacy and safety of a
basal-bolus insulin regimen comprising either insulin detemir or neural
protamine hagedorn (NPH) insulin in combination with mealtime insulin ... Cited by 193 - Related articles - View as HTML - All 5 versions
- ►diabetesjournals.org J Plank, M Bodenlenz, F Sinner, C Magnes, E … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Duration of action for insulin detemir was dose dependent and varied
from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6
units/kg, respectively. Interpolation of the dose-response relationships ... Cited by 129 - Related articles - All 9 versions
- ►fmmu.edu.cn [PDF] - Free from Publisher P Home, P Bartley, D Russell-Jones, H … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—With both insulin detemir groups, clinic fasting plasma glucose was
lower than with NPH insulin (IDet 12h vs. NPH, −1.5 mmol/l [95% CI −2.51 to
−0.48], P = 0.004; IDet morn+bed vs. NPH, −2.3 mmol/l (−3.32 to ... Cited by 152 - Related articles - BL Direct - All 7 versions
K Rašlová, M Bogoev, I Raz, G Leth, MA Gall … - Diabetes research and clinical practice, 2004 - Elsevier This trial compared the efficacy and safety of basal-bolus therapy using either
the soluble basal insulin analogue insulin detemir (IDet) in combination with
meal-time rapid-acting analogue insulin aspart (IAsp), or NPH insulin (NPH) ... Cited by 160 - Related articles - All 8 versions
D Russell-Jones, R Simpson, B Hylleberg, E … - Clinical therapeutics, 2004 - Elsevier Methods: This was a 6-month, prospective, randomized, open-label, controlled,
parallel-group trial conducted at 92 sites in Europe and Australia. The trial
population included men and women with type 1 DM for at least 1 year aged ... Cited by 122 - Related articles - All 4 versions
I De Leeuw, P Vague, JL Selam, S Skeie, H … - Diabetes Obesity and Metabolism, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 130 - Related articles - All 5 versions
O Klein, J Lynge, L Endahl, B Damholt, L … - Diabetes Obes Metab, 2007 - interscience.wiley.com Methods: Twenty-seven insulin-treated men with type 2 diabetes [body mass index
30.8 ± 2.6 kg/m 2 (mean ± sd), haemoglobin A 1c 7.6 ± 1.1%] were enrolled in
this randomized, double-blind trial and participated in six euglycaemic ... Cited by 71 - Related articles - All 4 versions
